- United States
- /
- Medical Equipment
- /
- NYSE:TFX
Teleflex First Quarter 2025 Earnings: EPS Beats Expectations
Teleflex (NYSE:TFX) First Quarter 2025 Results
Key Financial Results
- Revenue: US$700.7m (down 5.0% from 1Q 2024).
- Net income: US$95.1m (up by US$79.4m from 1Q 2024).
- Profit margin: 14% (up from 2.1% in 1Q 2024).
- EPS: US$2.08 (up from US$0.33 in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Teleflex EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%.
Looking ahead, revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 6.5% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Teleflex you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Teleflex might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:TFX
Teleflex
Designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
Moderate growth potential with imperfect balance sheet.
Similar Companies
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
SoFi Technologies: The Apex Aggregator and the Infrastructure of the Modern Financial System
CSL: The Dip Is the Opportunity
DHT Holdings, inc: Strait of Hormuz Risk Amidst US-Israel vs Iran Tensions Spikes VLCC Rates.
Recently Updated Narratives
China Is Growing 46%, The Stock Is Down 47%. Growth and Value Outside the US Market.
Indegene deep undervalued stock

VEON Ltd. (VEON): The Frontier "Digital Operator" and the 84% Hypergrowth Inflection
Popular Narratives
Nu holdings will continue to disrupt the South American banking market
SoFi Technologies: The Apex Aggregator and the Infrastructure of the Modern Financial System
